Target- |
MechanismApoptosis inducers |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2 Double-Blind Dose Escalation Study of KRN5500 for Neuropathic Pain in Patients With Cancer
The purpose of this study is to collect beginning information on whether intravenous (IV) administration of KRN5500 is safe and effective for treatment of neuropathic pain in patients with cancer.
100 Clinical Results associated with DARA Therapeutics, Inc.
0 Patents (Medical) associated with DARA Therapeutics, Inc.
100 Deals associated with DARA Therapeutics, Inc.
100 Translational Medicine associated with DARA Therapeutics, Inc.